"Efesovir" (FS-1) for COVID-19, Phase 2

Summary

Study of the efficacy and safety of the new drug "Efesovir" in comparison with the drug "Remdesivir" in the treatment of patients hospitalized with COVID-19. The hypothesis of clinical study is the clinical efficacy of new drug "Efesovir" is 10% to 30% higher than of "Remdesivir".

Timeline

Start

2025-12

Primary completion

2026-04

Completion

2026-11

Drugs

Indications